Contract awarded for products that bring improvement to the healthcare industry; HemoSonics’ Quantra Hemostasis System provides comprehensive whole blood coagulation analysis at the point of care in less than 15 minutes. DURHAM, N.C. – August 3, 2023 – HemoSonics®, a medical device technology company focused on acute bleeding management, today announced its Quantra® Hemostasis System […]
Next-Generation point-of-care whole blood hemostasis system now covers the broadest range of clinical indications in the U.S. to date. Durham, North Carolina – November, 30, 2022 – HemoSonics, LLC, a leading medical device company delivering individualized diagnostic solutions for Patient Blood Management (PBM), announced today that it has received 510(k) market clearance from the U.S. […]
Newly appointed Medical Director, Bruce Spiess, MD, FAHA to moderate the educational session “Listening to the Blood: An Update on the Quantra® System, the Latest Technology in the Management of Critical Bleeding” Clinical tools on display to provide actionable information to guide the management of critical bleeding enabling clinicians to choose the right treatment in […]
Charlottesville, VA, January 19, 2021 – HemoSonics welcomes the January 14th guidance of the US Food and Drug Administration (FDA) that broadens the use of viscoelastic coagulation analyzers for hospital patient healthcare settings in response to COVID-19. The FDA guidance is intended, for the duration of the COVID-19 public health emergency, to expand the availability […]
Charlottesville, VA – September 10, 2020 – HemoSonics announced today that its Quantra Desktop Remote Viewer Software (QDRV) has received a 510(k) clearance from the FDA. The QDRV enables remote access to its flagship product, the Quantra QPlus System. The Quantra System provides rapid, actionable coagulation results at the point of care – now viewable […]
How frequently do you have to run Quality Control (QC) on your viscoelastic testing (VET) device? What is the process for obtaining normal controls? How do you validate a new VET instrument for point-of-care use? These questions frequently arise when you are considering or evaluating a new VET point-of-care (POC) instrument. When it comes to […]
Charlottesville, VA – September 10, 2019 – HemoSonics is excited to announce that its new QStat Cartridge, an extension of its groundbreaking Quantra Hemostasis System, has registered for CE Mark and is now commercially available in Europe and Hong Kong. The utility of the Quantra System, which was previously available with the QPlus® Cartridge for […]
Charlottesville, VA, January 19, 2021 – HemoSonics welcomes the January 14th guidance of the US Food and Drug Administration (FDA) that broadens the use of viscoelastic coagulation analyzers for hospital patient healthcare settings in response to COVID-19. The FDA guidance is intended, for the duration of the COVID-19 public health emergency, to expand the availability […]
Charlottesville, VA – May 24, 2018 – HemoSonics today announced it will be participating in the scientific proceedings as well as have a commercial presence at Euroanesthesia (ESA), to be held in Copenhagen, Denmark on June 2-4th. HemoSonics will be participating in the ESA’s pre-congress session on Point of Care Guided Haemostatic Management During Massive […]
Following CE Mark in April, HemoSonics Targets Distribution Partners at MEDICA 2017 Charlottesville, VA – October 19, 2017 – HemoSonics today announced the appointment of Remi Corlin, a 20-year medical device and diagnostic industry veteran, as VP International Markets to lead the rollout of the Quantra Hemostasis Analyzer in markets outside of the US. The […]
